Elsevier Acquires Ariadne Genomics

12-Dec-2011 - Netherlands

Elsevier announced the acquisition of the business assets of Ariadne Genomics. Ariadne will be integrated with Elsevier’s Corporate Markets division.

“Ariadne Genomics’ pathway analysis tools and semantic technologies integrate research findings from across multiple content sources providing a deeper understanding of biological pathways and disease progression. Ariadne’s products improve research productivity and outcomes for life science researchers by delivering new insights for potential interventions, therapies and cures,” said Alexander van Boetzelaer, Managing Director of Elsevier Corporate Markets. “Ariadne brings to Elsevier an information offering in the biology domain and a passionate and dedicated team of life science professionals. Ariadne’s team and offerings are a powerful complement to our chemistry, pre-clinical and clinical workflow solutions.”

Ariadne’s CEO, Ilya Mazo, said of the acquisition, “With our integration into Elsevier, we look forward to strengthening our ability to serve biological researchers in scientific communities through further development of Pathway Studio, fortified with Elsevier’s content, and complementing Elsevier’s leadership role across biomedical disciplines.”

 Financial details of the acquisition are not being disclosed.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances